Cargando…

A Prospective, Comparative, Clinical Study to Evaluate the Safety and Efficacy of Two Different 0.1% Riboflavin Solutions Used in Collagen Crosslinking Treatment for Patients with Keratoconus

PURPOSE: To compare the safety and efficacy of 0.1% riboflavin in two different solutions which is used in corneal collagen crosslinking (CXL) for the treatment of keratoconus. METHODS: This was a prospective, randomized, comparison study which included 100 eyes of 61 patients with progressive kerat...

Descripción completa

Detalles Bibliográficos
Autores principales: Brar, Sheetal, Ganesh, Sri, Reddy, Shilpa S, BN, Nagesh, Shahanand, Dhwni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232965/
https://www.ncbi.nlm.nih.gov/pubmed/34188439
http://dx.doi.org/10.2147/OPTH.S313647
_version_ 1783713745807081472
author Brar, Sheetal
Ganesh, Sri
Reddy, Shilpa S
BN, Nagesh
Shahanand, Dhwni
author_facet Brar, Sheetal
Ganesh, Sri
Reddy, Shilpa S
BN, Nagesh
Shahanand, Dhwni
author_sort Brar, Sheetal
collection PubMed
description PURPOSE: To compare the safety and efficacy of 0.1% riboflavin in two different solutions which is used in corneal collagen crosslinking (CXL) for the treatment of keratoconus. METHODS: This was a prospective, randomized, comparison study which included 100 eyes of 61 patients with progressive keratoconus who underwent CXL with riboflavin 0.1% solution as a photosensitizer, using the standard Dresden protocol of using 3mW/cm(2) UV-A irradiation for 30 minutes which corresponds to a total energy of 5.4 J/cm(2). The recruited patients were divided into 2 groups ie, Flavin Group and Peschke-D group by computer generated randomization. Postoperative examinations were conducted on 1 day, 1 month, 3 months, 6 months and 12 months after the crosslinking. RESULTS: For both groups, the mean manifest spherical equivalent (SE), astigmatism, best corrected distance visual acuity, keratometry values, thinnest pachymetry values, demarcation line depth and endothelial cell density preoperatively and at postoperative 12 months were comparable with no statistically significant differences. At 12 months postoperatively, 62% of eyes in the Flavin group, and 68% of eyes in the Peschke-D group had postoperative manifest SE of within ± 1.00 D. During UV-A exposure, the cornea in the Flavin group showed intraoperative thinning of 112 microns (27%) as compared with a thinning of 108.12 microns (26.5%) observed in the Peschke group (p=1.67) from the initial pachymetry readings. No eye in either group had any immediate or long-term postop vision threatening complications such as infectious keratitis, corneal melt, non-resolving corneal oedema or endothelial decompensation. CONCLUSION: Both riboflavin solutions were equally safe and effective in the management of progressive keratoconus, and resulted in similar changes in terms of mean manifest spherical equivalent (SE), astigmatism, best corrected distance visual acuity, keratometry values, thinnest pachymetry values, demarcation line depth and endothelial cell density at the end of 12 months postoperatively. TRIAL REGISTRATION NUMBER: Ctri/2019/11/021841 (Www.ctri.nic.in).
format Online
Article
Text
id pubmed-8232965
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82329652021-06-28 A Prospective, Comparative, Clinical Study to Evaluate the Safety and Efficacy of Two Different 0.1% Riboflavin Solutions Used in Collagen Crosslinking Treatment for Patients with Keratoconus Brar, Sheetal Ganesh, Sri Reddy, Shilpa S BN, Nagesh Shahanand, Dhwni Clin Ophthalmol Original Research PURPOSE: To compare the safety and efficacy of 0.1% riboflavin in two different solutions which is used in corneal collagen crosslinking (CXL) for the treatment of keratoconus. METHODS: This was a prospective, randomized, comparison study which included 100 eyes of 61 patients with progressive keratoconus who underwent CXL with riboflavin 0.1% solution as a photosensitizer, using the standard Dresden protocol of using 3mW/cm(2) UV-A irradiation for 30 minutes which corresponds to a total energy of 5.4 J/cm(2). The recruited patients were divided into 2 groups ie, Flavin Group and Peschke-D group by computer generated randomization. Postoperative examinations were conducted on 1 day, 1 month, 3 months, 6 months and 12 months after the crosslinking. RESULTS: For both groups, the mean manifest spherical equivalent (SE), astigmatism, best corrected distance visual acuity, keratometry values, thinnest pachymetry values, demarcation line depth and endothelial cell density preoperatively and at postoperative 12 months were comparable with no statistically significant differences. At 12 months postoperatively, 62% of eyes in the Flavin group, and 68% of eyes in the Peschke-D group had postoperative manifest SE of within ± 1.00 D. During UV-A exposure, the cornea in the Flavin group showed intraoperative thinning of 112 microns (27%) as compared with a thinning of 108.12 microns (26.5%) observed in the Peschke group (p=1.67) from the initial pachymetry readings. No eye in either group had any immediate or long-term postop vision threatening complications such as infectious keratitis, corneal melt, non-resolving corneal oedema or endothelial decompensation. CONCLUSION: Both riboflavin solutions were equally safe and effective in the management of progressive keratoconus, and resulted in similar changes in terms of mean manifest spherical equivalent (SE), astigmatism, best corrected distance visual acuity, keratometry values, thinnest pachymetry values, demarcation line depth and endothelial cell density at the end of 12 months postoperatively. TRIAL REGISTRATION NUMBER: Ctri/2019/11/021841 (Www.ctri.nic.in). Dove 2021-06-21 /pmc/articles/PMC8232965/ /pubmed/34188439 http://dx.doi.org/10.2147/OPTH.S313647 Text en © 2021 Brar et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Brar, Sheetal
Ganesh, Sri
Reddy, Shilpa S
BN, Nagesh
Shahanand, Dhwni
A Prospective, Comparative, Clinical Study to Evaluate the Safety and Efficacy of Two Different 0.1% Riboflavin Solutions Used in Collagen Crosslinking Treatment for Patients with Keratoconus
title A Prospective, Comparative, Clinical Study to Evaluate the Safety and Efficacy of Two Different 0.1% Riboflavin Solutions Used in Collagen Crosslinking Treatment for Patients with Keratoconus
title_full A Prospective, Comparative, Clinical Study to Evaluate the Safety and Efficacy of Two Different 0.1% Riboflavin Solutions Used in Collagen Crosslinking Treatment for Patients with Keratoconus
title_fullStr A Prospective, Comparative, Clinical Study to Evaluate the Safety and Efficacy of Two Different 0.1% Riboflavin Solutions Used in Collagen Crosslinking Treatment for Patients with Keratoconus
title_full_unstemmed A Prospective, Comparative, Clinical Study to Evaluate the Safety and Efficacy of Two Different 0.1% Riboflavin Solutions Used in Collagen Crosslinking Treatment for Patients with Keratoconus
title_short A Prospective, Comparative, Clinical Study to Evaluate the Safety and Efficacy of Two Different 0.1% Riboflavin Solutions Used in Collagen Crosslinking Treatment for Patients with Keratoconus
title_sort prospective, comparative, clinical study to evaluate the safety and efficacy of two different 0.1% riboflavin solutions used in collagen crosslinking treatment for patients with keratoconus
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232965/
https://www.ncbi.nlm.nih.gov/pubmed/34188439
http://dx.doi.org/10.2147/OPTH.S313647
work_keys_str_mv AT brarsheetal aprospectivecomparativeclinicalstudytoevaluatethesafetyandefficacyoftwodifferent01riboflavinsolutionsusedincollagencrosslinkingtreatmentforpatientswithkeratoconus
AT ganeshsri aprospectivecomparativeclinicalstudytoevaluatethesafetyandefficacyoftwodifferent01riboflavinsolutionsusedincollagencrosslinkingtreatmentforpatientswithkeratoconus
AT reddyshilpas aprospectivecomparativeclinicalstudytoevaluatethesafetyandefficacyoftwodifferent01riboflavinsolutionsusedincollagencrosslinkingtreatmentforpatientswithkeratoconus
AT bnnagesh aprospectivecomparativeclinicalstudytoevaluatethesafetyandefficacyoftwodifferent01riboflavinsolutionsusedincollagencrosslinkingtreatmentforpatientswithkeratoconus
AT shahananddhwni aprospectivecomparativeclinicalstudytoevaluatethesafetyandefficacyoftwodifferent01riboflavinsolutionsusedincollagencrosslinkingtreatmentforpatientswithkeratoconus
AT brarsheetal prospectivecomparativeclinicalstudytoevaluatethesafetyandefficacyoftwodifferent01riboflavinsolutionsusedincollagencrosslinkingtreatmentforpatientswithkeratoconus
AT ganeshsri prospectivecomparativeclinicalstudytoevaluatethesafetyandefficacyoftwodifferent01riboflavinsolutionsusedincollagencrosslinkingtreatmentforpatientswithkeratoconus
AT reddyshilpas prospectivecomparativeclinicalstudytoevaluatethesafetyandefficacyoftwodifferent01riboflavinsolutionsusedincollagencrosslinkingtreatmentforpatientswithkeratoconus
AT bnnagesh prospectivecomparativeclinicalstudytoevaluatethesafetyandefficacyoftwodifferent01riboflavinsolutionsusedincollagencrosslinkingtreatmentforpatientswithkeratoconus
AT shahananddhwni prospectivecomparativeclinicalstudytoevaluatethesafetyandefficacyoftwodifferent01riboflavinsolutionsusedincollagencrosslinkingtreatmentforpatientswithkeratoconus